Anavex Life Sciences (NASDAQ:AVXL) executives used the company’s fiscal 2026 first-quarter earnings call to outline regulatory next steps for oral blarcamesine in early Alzheimer’s disease and to revi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results